Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma
ConclusionsOur results indicated that oAD-IL7 is a promising auxiliary therapy to improve the therapeutic efficacy of B7H3-CAR-T in glioblastoma by providing the activating signals for tumor-infiltrating T cells. Our results also lay the basis for the future clinical trials for the combination of IL7-loaded oncolytic adenovirus and CAR-T therapy for glioblastoma.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Adenoviruses | Allergy & Immunology | Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Study